Over the last years, several immune pathways in the skin have been identified. These discoveries have been translated into targeted therapies for inflammatory skin diseases, which have revolutionized our clinical practice. The perturbed molecular network in the skin may serve as a biomarker for disease prediction and as a source of targets for early therapeutic intervention or prevention. With rising costs, this disease-focused healthcare model will become unsustainable, therefore next-generation healthcare must not focus solely on treatment personalisation (the right treatment for the right patient), but also needs to shift its focus towards disease prevention and early therapeutic intervention prior to disease manifestation.